Shadow

Cloud PR Wire

Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant

Cloud PR Wire
–News Direct– By David Willey, Benzinga Read the latest report on NanoViricides here The CDC recently issued a warning that Respiratory Syncytial Virus (RSV), a common and highly contagious lung infection that can cause bronchitis and pneumonia, is on the rise in the Southeastern United States and the very young and the elderly are the most at risk of developing severe incidences of RSV. Every year, there are over 2 million outpatient (non-hospitalized) cases of RSV in children under 5, and RSV is the leading cause of hospitalizations for young children. There are up to 80,000 hospitalization cases for children under 5, and there are also up to 160,000 cases of patients over 65 getting hospitalized with RSV. Up to 300 children under 5 and 10,000 adults over 65 die of RSV annually. Despi...

Integrated Facilities Management Pioneer NEST Releases Inaugural Social Responsibility Report

Cloud PR Wire
–News Direct– NEST, the pioneer of integrated facilities management, released its inaugural Social Responsibility Report, highlighting the companys environmental stewardship, social programming, diversity, equity, inclusion, and ethics. The report revealed new impactful programs, including Trees for ISPs, where NEST plants a tree for select work completed through its network of 26,000 Independent Service Providers (ISPs). We recognize that our work at NEST impacts thousands of companies, employees, and the environment, said Rob Almond, CEO of NEST. We believe that true success means making a positive impact through every facet of our operation. With this vision at our core, we are proud to present our inaugural Social Responsibility Report and offer a transparent overview of our accompli...

Marketing 2.0 Conference To Review The Escalating Threat Of Bot Traffic Scams

Cloud PR Wire
The esteemed Marketing 2.0 Conference has announced a comprehensive review session on bot traffic scams, offering marketers unparalleled insights into this menace. Las Vegas, Nevada Sep 19, 2023 (Issuewire.com) – The prestigious Marketing 2.0 Conference, scheduled at Caesars Palace on March 18-20, 2024, is poised to address a challenge that has become alarmingly prevalent in the digital age: bot traffic scams. As technology grows, so do these illegitimate tricks, making it even more vital for people to stay alert and informed. As businesses and marketers invest time, effort, and resources in creating impactful digital campaigns, bot traffic scams emerge as unsettling disruptors. These scams, often mistaken as legitimate traffic, diminish the value of genuine user interactions. Their pr...

Graft Polymer’s new Slovenian plant key to unlocking industrial-scale solutions

Cloud PR Wire
–News Direct– Welcome to Wednesday's business update. In this video, we focus on Graft Polymer (UK) PLC's milestonethe commissioning of its expanded Slovenian plant. Chairman Roby Zomer says this new facility doubles the company's production capacity to 6,000 tonnes per year and opens doors for industrial-scale partnerships. We'll also delve into the company's recent contract achievements, including a significant U.S. approval for its GraftBio drug delivery system. Where it has been approved for sale over-the- counter as a part of the MGC Pharma ArtemiC COVID treatment. Stay tuned as we explore how these developments are setting the stage for Graft Polymer's future growth and market expansion. The core business of the group comprises polyme...

BestGrowthStocks.com Issues a Comprehensive Analysis of Avalo Therapeutics

Cloud PR Wire
–News Direct– NEW YORK, NY / NewsDirect / September 27th, 2023 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued an extensive analysis on Avalo Therapeutics Inc a clinical-stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. Avalo Therapeutics Inc (NASDAQ: AVTX) recently announced the elimination of $35 million in debt paving the way for future growth and innovation. Best Growth Stock's full report breaks through the noise and offers a full comprehensive and easy-to-understand analysis of Avalos securities, recent events, earnings, pipeline, ...